Skip to main content
OpenTrials
Completed

NCT Number: NCT02038309

Persistent Platelet Reactivity in Acute Coronary Syndrome

Study of persistent platelet reactivity during acute coronary syndrome. Patients are included at admission to the hospital. Platelet aggregation is evaluated by platelet function testing after blood sampling during hospitalization. No changes in treatment is planned.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Cardiology - Lariboisiere Hospital

Paris, 75010, France

About this study

Blood samples are performed on day 2 and 4 and collected with usual blood samples and analyzed by the laboratory. Maximal aggregation intensity and velocity are measured by light transmission aggregometry induced by arachidonic acid (AA) or adenosine diphosphate (ADP). Platelet function analyzer will be also used. No changes in treatment in response to the results is planned.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute coronary syndrome with elevation in troponin

Exclusion criteria

  • anticoagulant treatment

Treatment and study plan

Primary outcomes

  1. maximum aggregation intensity

    Time frame: day 2

    Light transmission aggregometry following exposition to arachidonic acid 0.5mg/ml during the acute phase (day2-day 5)

Secondary outcomes

  1. Maximum aggregation intensity

    Time frame: Day 2

    Light transmission aggregometry following exposition to adenosine diphosphate during the acute phase (day2-day 5) and during the chronic phase (day 30-day 60)

  2. Maximum aggregation intensity

    Time frame: Chronic phase (day 30 to day 60)

    Light transmission aggregometry following exposition to arachidonic acid 0.5mg/ml during the chronic phase (day 30-day 60)

Other outcomes

  1. Major cardiovascular and cerebrovascular events (MACCE)

    Time frame: one year

    Major cardiovascular and cerebrovascular events : death, myocardial infarction, stroke, rehospitalisation and bleeding (academic research consortium) events at 1 year

  2. microvascular resistance index

    Time frame: Day 1

    measurement during primary PCI on admission

Sponsors and collaborators

Lead sponsor

Hopital Lariboisière

Other

Registry information

Important dates

Study start
2013
Primary completion
2013
Study completion
2015
First posted
Jan 16, 2014
Registry last updated
Jul 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.